TMCI TREACE MED CONCEPTS INC revenue, earnings and financials

For the quarter ended June 30, 2026, TREACE MED CONCEPTS INC reported revenue of $45.4M (down 4.2% from a year earlier), net income of −$15.9M and diluted EPS of −$0.24; over the last four quarters revenue was $205M and net income −$59.5M; for the fiscal year ended December 2025 revenue was $213M, up 1.6% on the year before.

TMCI annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $213M, gross profit $170M, operating income −$54.2M, net income −$59.0M (margin -27.7%), EPS −$0.93
• Fiscal year ended Dec 2024: revenue $209M, gross profit $168M, operating income −$55.7M, net income −$55.7M (margin -26.6%), EPS −$0.90
• Fiscal year ended Dec 2023: revenue $187M, gross profit $152M, operating income −$51.4M, net income −$50.0M (margin -26.7%), EPS −$0.81
• Fiscal year ended Dec 2022: revenue $142M, gross profit $116M, operating income −$34.8M, net income −$43.0M (margin -30.3%), EPS −$0.77
• Fiscal year ended Dec 2021: revenue $94.4M, gross profit $77.5M, operating income −$16.5M, net income −$20.6M (margin -21.8%), EPS −$0.43

TMCI quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $45.4M (down 4.2% year over year), net income −$15.9M, EPS −$0.24
• Quarter ended Mar 31, 2026: revenue $47.2M (down 10.2% year over year), net income −$18.0M, EPS −$0.28
• Quarter ended Dec 31, 2025 (from the annual report): revenue $62.5M (down 9.0% year over year), net income −$9.39M, EPS −$0.14
• Quarter ended Sep 30, 2025: revenue $50.2M (up 11.4% year over year), net income −$16.3M, EPS −$0.26
• Quarter ended Jun 30, 2025: revenue $47.4M (up 6.6% year over year), net income −$17.4M, EPS −$0.28
• Quarter ended Mar 31, 2025: revenue $52.6M (up 2.9% year over year), net income −$15.9M, EPS −$0.25
• Quarter ended Dec 31, 2024 (from the annual report): revenue $68.7M (up 10.4% year over year), net income −$501K, EPS −$0.01
• Quarter ended Sep 30, 2024: revenue $45.1M (up 10.6% year over year), net income −$15.4M, EPS −$0.25
• Quarter ended Jun 30, 2024: revenue $44.5M (up 6.0% year over year), net income −$21.2M, EPS −$0.34
• Quarter ended Mar 31, 2024: revenue $51.1M (up 21.1% year over year), net income −$18.7M, EPS −$0.30
• Quarter ended Dec 31, 2023 (from the annual report): revenue $62.2M (up 25.0% year over year), net income −$6.75M, EPS −$0.10
• Quarter ended Sep 30, 2023: revenue $40.8M (up 23.3% year over year), net income −$17.5M, EPS −$0.28
• Quarter ended Jun 30, 2023: revenue $42.0M (up 40.0% year over year), net income −$12.3M, EPS −$0.20
• Quarter ended Mar 31, 2023: revenue $42.2M (up 45.3% year over year), net income −$13.5M, EPS −$0.23
• Quarter ended Dec 31, 2022 (from the annual report): revenue $49.8M (up 48.8% year over year), net income −$4.60M, EPS −$0.08
• Quarter ended Sep 30, 2022: revenue $33.1M (up 52.9% year over year), net income −$12.1M, EPS −$0.22
• Quarter ended Jun 30, 2022: revenue $30.0M (up 45.1% year over year), net income −$17.2M, EPS −$0.31
• Quarter ended Mar 31, 2022: revenue $29.0M (up 55.3% year over year), net income −$9.04M, EPS −$0.16
• Quarter ended Dec 31, 2021 (from the annual report): revenue $33.4M, net income −$6.62M, EPS −$0.14
• Quarter ended Sep 30, 2021: revenue $21.6M, net income −$6.42M, EPS −$0.12

TMCI cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$16.0M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$37.2M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$34.6M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$30.6M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$17.2M, share buybacks n/a

TMCI balance sheet

• Jun 30, 2026: cash $12.6M, total assets $181M, total liabilities $113M, shareholders' equity $67.7M, long-term debt $56.0M
• Mar 31, 2026: cash $9.54M, total assets $184M, total liabilities $107M, shareholders' equity $77.2M, long-term debt $55.8M
• Dec 31, 2025: cash $10.7M, total assets $191M, total liabilities $103M, shareholders' equity $87.3M, long-term debt $55.6M
• Sep 30, 2025: cash $7.69M, total assets $197M, total liabilities $107M, shareholders' equity $89.2M, long-term debt $53.5M
• Jun 30, 2025: cash $8.05M, total assets $206M, total liabilities $109M, shareholders' equity $97.6M, long-term debt $53.5M
• Mar 31, 2025: cash $13.4M, total assets $206M, total liabilities $101M, shareholders' equity $105M, long-term debt $53.4M
• Dec 31, 2024: cash $11.4M, total assets $217M, total liabilities $104M, shareholders' equity $113M, long-term debt $53.3M
• Sep 30, 2024: cash $12.1M, total assets $213M, total liabilities $108M, shareholders' equity $105M, long-term debt $53.2M

What is TMCI's revenue?

TREACE MED CONCEPTS INC reported $205M of revenue over its last four quarters, through June 30, 2026.

Is TMCI profitable?

No. TREACE MED CONCEPTS INC lost $59.5M over the last four quarters.

What is TMCI's EPS?

Diluted earnings per share over the last four quarters were −$0.92; −$0.24 in the latest quarter.

TMCI ownership and insider trades · All stocks